From sentinel to messenger: an extended phenotypic analysis of the monocyte to dendritic cell transition.
The transitional stages in the relationship between sentinel monocytes and messenger dendritic cells that are active in adaptive immunity, are, as yet, unclear. To explore these events, 2-hr adherent peripheral blood mononuclear cells were used either as monocytes, or cultured for 7 days with granulocyte-macrophage colony-stimulating factor (GM-CSF) and interleukin-4 (IL-4) to generate dendritic cells, and the phenotypic features and relationship of the two cell populations was investigated using an extensive panel of monoclonal antibodies (mAbs). The features of the shift from monocyte to dendritic cell were also examined by daily phenotyping during the 7-day culture period. Twenty-five mAbs, most of which recognized known CD molecules, bound both monocytes and dendritic cells equally, whereas 19 mAbs exhibited differential staining. Four molecules not previously reported on dendritic cells were documented: CD87, CD98, CD147 and CD148. Seven cell-surface molecules (HLA-DQ, CD1a, CD13, CD30, CD43, CD63 and CD86) were expressed either at very low levels or not at all on monocytes, but had a strikingly increased expression on dendritic cells, suggesting a role in antigen presentation. The kinetics of monocyte to dendritic cell transition revealed a rapid activation phase within the first 24 hr, with a considerable increase in expression of the activation markers HLA-DR, CD13, CD14 and CD98; this was followed by a down-regulation of CD14 and a more gradual development of the other dendritic cell features over the remaining 6 days, with steady increases in CD1a, CD18, CD43, CD86, HLA-DR and HLA-DQ. Thus, these studies have demonstrated four novel components of the dendritic cell, and have documented the dynamic multistep nature of the process whereby an antigen-presenting dendritic cell phenotype may emerge from a monocyte precursor.
Department of Immunology, Windeyer Institute of Medical Sciences, University College London Medical School, London, UK.
V E
VE
Woodhead
M H
MH
Binks
B M
BM
Chain
D R
DR
Katz
D000818:Animals; D000911:Antibodies, Monoclonal; D015703:Antigens, CD / Q000276:immunology; D018949:Antigens, CD1 / Q000276:immunology; D051940:B7-2 Antigen; D015415:Biomarkers / Q000032:analysis; D018826:CD13 Antigens / Q000276:immunology; D018821:CD18 Antigens / Q000276:immunology; D002352:Carrier Proteins / Q000276:immunology; D002454:Cell Differentiation; D002478:Cells, Cultured; D003713:Dendritic Cells / Q000166:cytology*; D005434:Flow Cytometry; D005455:Fluorescent Antibody Technique; D027261:Fusion Regulatory Protein-1; D006683:HLA-DQ Antigens / Q000032:analysis; D006684:HLA-DR Antigens / Q000032:analysis; D051917:Leukosialin; D018950:Lipopolysaccharide Receptors / Q000276:immunology; D008562:Membrane Glycoproteins / Q000276:immunology; D051379:Mice; D009000:Monocytes / Q000166:cytology*; D010641:Phenotype; D017027:Protein Tyrosine Phosphatases / Q000276:immunology; D054631:Receptor-Like Protein Tyrosine Phosphatases, Class 3; D011956:Receptors, Cell Surface / Q000276:immunology; D055293:Receptors, Urokinase Plasminogen Activator; D012795:Sialoglycoproteins / Q000276:immunology
D000911:Antibodies, Monoclonal; D015703:Antigens, CD; D018949:Antigens, CD1; D051940:B7-2 Antigen; D015415:Biomarkers; D018821:CD18 Antigens; D002352:Carrier Proteins; C497965:Cd86 protein, mouse; D027261:Fusion Regulatory Protein-1; D006683:HLA-DQ Antigens; D006684:HLA-DR Antigens; D051917:Leukosialin; D018950:Lipopolysaccharide Receptors; D008562:Membrane Glycoproteins; C524899:Plaur protein, mouse; D011956:Receptors, Cell Surface; D055293:Receptors, Urokinase Plasminogen Activator; D012795:Sialoglycoproteins; C497863:Spn protein, mouse; D017027:Protein Tyrosine Phosphatases; C098066:Ptprj protein, mouse; D054631:Receptor-Like Protein Tyrosine Phosphatases, Class 3; D018826:CD13 Antigens